{"componentChunkName":"component---src-templates-chapter-level-2-chapter-level-2-tsx","path":"/topics/rheumatoid-arthritis/management/confirmed-ra/","result":{"pageContext":{"chapter":{"id":"0ba5ec6e-3f0f-5157-8e24-55ef24b2cfe9","slug":"confirmed-ra","fullItemName":"Scenario: Confirmed RA","depth":2,"htmlHeader":"<!-- begin field 4fcad1ba-acbe-417a-9f24-e263a08693e8 --><h2>Scenario: Confirmed rheumatoid arthritis</h2><!-- end field 4fcad1ba-acbe-417a-9f24-e263a08693e8 -->","summary":"Covers the management of people with RA in primary care.","htmlStringContent":"<!-- begin item 2417bdda-339b-4bc6-974b-e7bc2563a3a5 --><!-- begin field 032c7616-4810-4e67-8844-acbc015bf8ab --><p>From age 16 years onwards.</p><!-- end field 032c7616-4810-4e67-8844-acbc015bf8ab --><!-- end item 2417bdda-339b-4bc6-974b-e7bc2563a3a5 -->","topic":{"id":"80425c66-11ed-5a54-aecf-455f339cb0cd","topicId":"d9596563-d663-48ca-8d6a-4ddeb263b46e","topicName":"Rheumatoid arthritis","slug":"rheumatoid-arthritis","lastRevised":"Last revised in April 2020","chapters":[{"id":"e5b4cb7c-c830-59e0-a369-a8151bd28e7c","fullItemName":"Summary","slug":"summary","subChapters":[]},{"id":"28d53d37-f5b2-5ab0-bd6f-6c6858fc63e4","fullItemName":"Have I got the right topic?","slug":"have-i-got-the-right-topic","subChapters":[]},{"id":"8eb76d85-83a8-5bb1-be89-15a9e86def8d","fullItemName":"How up-to-date is this topic?","slug":"how-up-to-date-is-this-topic","subChapters":[{"id":"7eba8b39-2fb0-52b0-8988-5d108c1720fa","slug":"changes","fullItemName":"Changes"},{"id":"add57644-4b68-5377-b8ce-b0cc395570f0","slug":"update","fullItemName":"Update"}]},{"id":"62d68b4b-4522-5afb-88fe-48b87fc31a2d","fullItemName":"Goals and outcome measures","slug":"goals-outcome-measures","subChapters":[{"id":"f9fe7005-bf48-5a4e-bc7c-08550e792a18","slug":"goals","fullItemName":"Goals"},{"id":"cc0b2b43-25e2-5936-ad94-217419fd0126","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"6a0fead6-ca32-5399-9b1b-22b31fc0c765","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"f76001a5-99f4-5086-bc05-c1cd7535aab0","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"fb29501f-d465-5652-b659-ffb4e5c8e928","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation"},{"id":"3181265d-dee9-5587-974d-b4bae95c10ee","slug":"nice-quality-standards","fullItemName":"NICE quality standards"}]},{"id":"167941e5-411a-5afd-94af-8e7725b24b1a","fullItemName":"Background information","slug":"background-information","subChapters":[{"id":"bb48f4e9-23c4-5828-bccb-666f4dbc512d","slug":"definition","fullItemName":"Definition"},{"id":"06cc7595-3f6c-59d6-929b-964159afde4d","slug":"prevalence-incidence","fullItemName":"Prevalence and incidence"},{"id":"8fb1fc93-039a-5d6b-a86d-aeb61578f11d","slug":"complications","fullItemName":"Complications"}]},{"id":"e352008d-7a0c-55ba-b778-c6218ef4ef69","fullItemName":"Diagnosis","slug":"diagnosis","subChapters":[{"id":"b9d257ab-0ebb-52bf-908a-8ebebe6c550c","slug":"when-to-suspect-ra","fullItemName":"When to suspect RA"},{"id":"25d80dc3-ea8a-5560-8a0b-3a64b87c5690","slug":"differential-diagnosis","fullItemName":"Differential diagnosis"},{"id":"5de822df-3081-5ed6-a21b-e3e2925436bd","slug":"investigations-for-suspected-ra","fullItemName":"Investigations for suspected RA"}]},{"id":"6f1e7941-f462-5d64-8822-8328310b81b9","fullItemName":"Management","slug":"management","subChapters":[{"id":"2ed609a5-1052-56f5-b263-63d4e5325949","slug":"suspected-ra","fullItemName":"Scenario: Suspected RA"},{"id":"0ba5ec6e-3f0f-5157-8e24-55ef24b2cfe9","slug":"confirmed-ra","fullItemName":"Scenario: Confirmed RA"},{"id":"c490cb4d-f228-5c81-b9f2-0ac419b6d60a","slug":"covid-19","fullItemName":"Scenario: COVID-19"}]},{"id":"13cb1ed1-b962-5e8a-88c8-8b7185af06df","fullItemName":"Supporting evidence","slug":"supporting-evidence","subChapters":[]},{"id":"e875cc8d-258b-5535-9d34-40f03cb150c7","fullItemName":"How this topic was developed","slug":"how-this-topic-was-developed","subChapters":[{"id":"9b45cf27-1cfb-591d-a936-5e49910f88ac","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"93bd3cb0-31a7-5acf-bc5f-8858b54e466b","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"a24a6436-a685-5277-8c22-524ebe895154","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"4258a438-16bd-591d-bd95-5d6a682e1696","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"58298e48-e237-5259-b79b-da11e96f0a4e","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"6c1abdea-39c1-5537-8e4f-6e6ff3a71736","fullItemName":"References","slug":"references","subChapters":[]}]},"parentChapter":{"id":"6f1e7941-f462-5d64-8822-8328310b81b9","slug":"management","fullItemName":"Management"},"subChapters":[{"id":"9cee3e38-a272-5e3f-a39e-8c5f5fe5ad1a","slug":"drug-treatments","fullItemName":"Drug treatments","depth":3,"htmlHeader":"<!-- begin field e25addfa-1e98-44d1-8973-af41d2cf8aba --><h3>What drug treatments may be offered in secondary care for rheumatoid arthritis?</h3><!-- end field e25addfa-1e98-44d1-8973-af41d2cf8aba -->","summary":null,"htmlStringContent":"<!-- begin item 7694bec1-2e8b-4689-8671-5357e1e491ff --><!-- begin field 070b4a59-3d8b-4f10-afbf-a436c735689a --><ul><li>A treat to target strategy is used — the aim is to achieve a target of remission or low disease activity if remission cannot be achieved. </li><li>Specialists will usually offer a conventional disease modifying anti-rheumatic drug (cDMARD) as monotherapy, ideally within 3 months of the onset of symptoms — for example, oral methotrexate, leflunomide, or sulfasalazine. The dose is increased depending on tolerance until the treatment target is achieved.<ul><li>Hydroxychloroquine may be used as an alternative for people with palindromic disease. </li><li>Short-term bridging treatment with glucocorticoids (oral, intramuscular or intra-articular) may be used when starting a new cDMARD to improve symptoms while waiting for the new DMARD to take effect (which can take 2–3 months).</li><li>Additional cDMARDs may be offered in combination in a step-up strategy when the treatment target (remission or low disease activity) has not been achieved despite dose escalation.</li><li>Once the treatment target has been achieved drug doses may be stepped down or stopped.</li></ul></li><li>If the disease is severe and has not responded to intensive therapy with a combination of cDMARDs, biological DMARDs may be offered in combination with methotrexate, or alone (depending on the product licence) for people who cannot take methotrexate because it is contraindicated or because of intolerance. For more information see the section on <a class=\"topic-reference external-reference\" href=\"/topics/dmards/background-information/indications/#biologics\">Indications for biologics</a> in the CKS topic on <a class=\"topic-reference external-reference\" href=\"/topics/dmards/\">DMARDs</a>.    </li><li>DMARDs require regular monitoring with blood tests. This may be done in secondary care but can be carried out in primary care under a shared care agreement. For more information, see the section on <a class=\"topic-reference external-reference\" href=\"/topics/dmards/management/general-principles-of-managing-dmards/#general-principles-of-managing-dmards\">General principles of managing DMARDs</a> in the CKS topic on <a class=\"topic-reference external-reference\" href=\"/topics/dmards/\">DMARDs</a>.</li><li>Glucocorticoids may be offered short-term treatment to manage flares in people with recent-onset or established disease to rapidly decrease inflammation.<ul><li>In people with established RA, glucocorticoids will only be continued long-term when the long-term complications of glucocorticoid therapy have been fully discussed, and all other treatment options (including biological and targeted synthetic DMARDs) have been offered.</li></ul></li></ul><!-- end field 070b4a59-3d8b-4f10-afbf-a436c735689a --><!-- end item 7694bec1-2e8b-4689-8671-5357e1e491ff -->","subChapters":[{"id":"b9ab7a72-e138-5c12-bb9f-a4962d0e33d5","slug":"basis-for-recommendation-24f","fullItemName":"Basis for recommendation","depth":4,"htmlHeader":"<!-- begin field 63064164-0882-4311-b61f-0049b42e0c69 --><h4>Basis for recommendation</h4><!-- end field 63064164-0882-4311-b61f-0049b42e0c69 -->","summary":null,"htmlStringContent":"<!-- begin item 24fe6c4e-e120-47b9-92bc-aa90468813e0 --><!-- begin field 786ad592-3f1a-4517-ac65-afea009a38b6 --><p>These recommendations are based on the National Institute for Health and Care Excellence (NICE) guideline <em>Rheumatoid arthritis in adults: management </em>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/rheumatoid-arthritis/references/\">NICE, 2018a</a>], the NICE pathway<em> </em><em>Drug treatment for rheumatoid arthritis </em>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/rheumatoid-arthritis/references/\">NICE, 2018e</a>], the<em> American College of Rheumatology (ACR) Guideline for the treatment of rheumatoid arthritis</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/rheumatoid-arthritis/references/\">ACR, 2015</a>], and the European League Against Rheumatism (EULAR) <em>2016 update of the EULAR recommendations for the management of early arthritis </em>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/rheumatoid-arthritis/references/\">Combe, 2016</a>].</p><ul><li>NICE does not recommend a preference for first line therapy [<a class=\"bibliography-reference internal-reference\" href=\"/topics/rheumatoid-arthritis/references/\">NICE, 2018a</a>], however the ACR suggests that methotrexate should be the preferred initial treatment for most people with rheumatoid arthritis [<a class=\"bibliography-reference internal-reference\" href=\"/topics/rheumatoid-arthritis/references/\">ACR, 2015</a>], and EULAR recommends that methotrexate should be part of the first treatment strategy for people at risk of persistent disease, unless contraindicated [<a class=\"bibliography-reference internal-reference\" href=\"/topics/rheumatoid-arthritis/references/\">Combe, 2016</a>]. </li></ul><!-- end field 786ad592-3f1a-4517-ac65-afea009a38b6 --><!-- end item 24fe6c4e-e120-47b9-92bc-aa90468813e0 -->","subChapters":[]}]},{"id":"62ff460d-63f0-572a-9329-025c9845bcc8","slug":"role-of-primary-care","fullItemName":"Role of primary care","depth":3,"htmlHeader":"<!-- begin field ac84c3b8-cce7-4067-8779-b29df1ca4b73 --><h3>What is the role of primary care in the management of someone with confirmed rheumatoid arthritis?</h3><!-- end field ac84c3b8-cce7-4067-8779-b29df1ca4b73 -->","summary":null,"htmlStringContent":"<!-- begin item f44918fd-8e46-4fcc-9b0a-d44003fd31f0 --><!-- begin field 97ad6176-5a2c-4583-90b3-02598373f91d --><ul><li>The role of primary care as part of the multidisciplinary team managing people with rheumatoid arthritis (RA) is to: <ul><li>Ensure that all adults with RA have:<ul><li>Rapid access to specialist care for flares.</li><li>Information about when and how to access specialist care — for example, check the person has a named rheumatology specialist nurse who coordinates care and has access to physiotherapy, occupational therapy and podiatry services for advice on mobility, pain control, work-related issues and foot health.</li><li>Ongoing drug monitoring — offer regular medication reviews to check concordance, ask about adverse effects and manage where appropriate. For more information, see the CKS topics on <a class=\"topic-reference external-reference\" href=\"/topics/dmards/\">DMARDs</a> (for details of the blood monitoring required for individual DMARDs if this is not carried out in secondary care) and <a class=\"topic-reference external-reference\" href=\"/topics/nsaids-prescribing-issues/\">NSAIDs - prescribing issues</a>.</li></ul></li><li>Ensure all people with RA, including those who have achieved the treatment target, are offered an annual review (this may be coordinated by rheumatology) to:<ul><li>Assess disease activity and damage, and measure functional ability (using, for example, the Health Assessment Questionnaire [HAQ])</li><li>Check for the development of comorbidities, such as hypertension, ischaemic heart disease, osteoporosis and depression. For more information, see the CKS topics on <a class=\"topic-reference external-reference\" href=\"/topics/cvd-risk-assessment-management/\">CVD risk assessment and management</a>, <a class=\"topic-reference external-reference\" href=\"/topics/hypertension-not-diabetic/\">Hypertension - not diabetic</a>, <a class=\"topic-reference external-reference\" href=\"/topics/smoking-cessation/\">Smoking cessation</a>, <a class=\"topic-reference external-reference\" href=\"/topics/alcohol-problem-drinking/\">Alcohol - problem drinking</a>, <a class=\"topic-reference external-reference\" href=\"/topics/osteoporosis-prevention-of-fragility-fractures/\">Osteoporosis - prevention of fragility fractures</a>, <a class=\"topic-reference external-reference\" href=\"/topics/falls-risk-assessment/\">Falls - risk assessment</a>, and <a class=\"topic-reference external-reference\" href=\"/topics/depression/\">Depression</a>.</li><li>Assess symptoms that suggest complications, such as vasculitis and disease of the cervical spine, lung or eyes.</li><li>Organise appropriate cross referral within the multidisciplinary team.</li><li>Assess the need for referral for surgery.</li><li>Assess the effect the disease is having on the person's life.</li></ul></li><li>Identify flares of RA, and manage these appropriately — for more information, see the section on <a class=\"topic-reference internal-reference\" href=\"/topics/rheumatoid-arthritis/management/confirmed-ra/#management-of-an-ra-flare\">Management of an RA flare</a>.</li><li>Liaise with the person's specialist team, particularly in relation to changes in medication.</li><li>Offer pneumococcal and yearly influenza vaccinations, if necessary — for more information, see the CKS topics on <a class=\"topic-reference external-reference\" href=\"/topics/immunizations-pneumococcal/\">Immunizations - pneumococcal</a> and <a class=\"topic-reference external-reference\" href=\"/topics/immunizations-seasonal-influenza/\">Immunizations - seasonal influenza</a>.</li><li>Improve the person's understanding of RA. For more information see the <a data-hyperlink-id=\"ee8e0286-a51b-46db-bf1e-a93100aa4c92\" href=\"http://www.arthritiscare.org.uk/Home\">Arthritis Care</a>, <a data-hyperlink-id=\"4a2fccee-493c-4435-8f24-a93100aa4d15\" href=\"http://www.arthritisresearchuk.org/\">Arthritis Research UK</a>, and <a data-hyperlink-id=\"5f215b15-c7ff-49b2-b653-a93100aa4d74\" href=\"http://www.rheumatoid.org.uk/\">National Rheumatoid Arthritis Society</a> websites.</li></ul></li></ul><!-- end field 97ad6176-5a2c-4583-90b3-02598373f91d --><!-- end item f44918fd-8e46-4fcc-9b0a-d44003fd31f0 -->","subChapters":[{"id":"d1aa3c3d-c5a6-52b9-b5be-01aaff7d7d9c","slug":"basis-for-recommendation-550","fullItemName":"Basis for recommendation","depth":4,"htmlHeader":"<!-- begin field 77c308e1-5508-4897-96b1-e9a5036437d2 --><h4>Basis for recommendation</h4><!-- end field 77c308e1-5508-4897-96b1-e9a5036437d2 -->","summary":null,"htmlStringContent":"<!-- begin item 5504727f-0089-4395-98f4-80b819ab4eb2 --><!-- begin field 4c945af2-efd3-4c4a-b20b-ef1ab5d3cc0e --><p>These recommendations are based on the National Institute for Health and Care Excellence (NICE) guideline <em>Rheumatoid arthritis: national clinical guideline for management and treatment in adults </em>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/rheumatoid-arthritis/references/\">National Collaborating Centre for Chronic Conditions, 2018</a>] and what CKS considers good clinical practice.</p><!-- end field 4c945af2-efd3-4c4a-b20b-ef1ab5d3cc0e --><!-- end item 5504727f-0089-4395-98f4-80b819ab4eb2 -->","subChapters":[]}]},{"id":"0db694e8-5600-5408-9511-598b5b158ed8","slug":"management-of-an-ra-flare","fullItemName":"Management of an RA flare","depth":3,"htmlHeader":"<!-- begin field 7689ad6e-3a0d-41b0-8a88-af3a7cf4f7ab --><h3>How should I manage a flare of rheumatoid arthritis?</h3><!-- end field 7689ad6e-3a0d-41b0-8a88-af3a7cf4f7ab -->","summary":null,"htmlStringContent":"<!-- begin item e18069ee-efb8-4c92-8988-dbaa03de34e9 --><!-- begin field ab3ef5a9-535a-4fe7-a6c6-11dde6cdaaf2 --><ul><li><strong>Exclude septic arthritis </strong>(suspect this if a single joint is hot and swollen, especially if there are signs of sepsis). </li><li><strong>Suspect a flare of rheumatoid arthritis (RA) </strong>if there are worsening:<ul><li>Symptoms of stiffness, pain, joint swelling, or general fatigue.</li><li>Signs of joint synovitis, joint tenderness, or loss of joint function.</li><li>Inflammatory markers — for example, an increase in C-reactive protein from previous levels.</li></ul></li><li><strong>Consider and manage other <a class=\"topic-reference internal-reference\" href=\"/topics/rheumatoid-arthritis/management/confirmed-ra/#other-causes-of-worsening-joint-symptoms\">causes</a> of worsening symptoms.</strong></li><li><strong>Seek specialist advice about management. O</strong><strong>ffer short-term treatment with glucocortiocids, either: </strong><ul><li>An intra-articular glucocorticoid injection (for example, methylprednisolone acetate or triamcinolone acetonide) for a localized RA flare, if the expertise is available in primary care.<ul><li>The dose of is dependent on the size of the joint and the severity of the condition.</li></ul></li><li>An intramuscular glucocorticoid, if an intra-articular glucocorticoid is not possible or appropriate. Options include:<ul><li>Methylprednisolone acetate (40 mg in 1 ml) — give 1 ml (40 mg) to 3 ml (120 mg) by deep intramuscular injection into the gluteal muscle.</li><li>Triamcinolone acetonide (40 mg in 1 ml) — give 1 ml (40 mg) by deep intramuscular injection into the gluteal muscle.</li></ul></li><li>An oral glucocorticoid, if it is not practical to give an intramuscular glucocorticoid. A reducing course of an oral glucocorticoid over 2-4 weeks can be started whilst awaiting specialist assessment: <ul><li>For a 2-week course: prednisolone 10 mg daily for 7 days, then 5 mg daily for 7 days, then stop.</li><li>For a 3-week course: prednisolone 15 mg daily for 7 days, then 10 mg daily for 7 days, then 5 mg daily for 7 days, then stop.</li><li>For a 4-week course: prednisolone 20 mg daily for 7 days, then 15 mg daily for 7 days, then 10 mg daily for 7 days, then 5 mg daily for 7 days, then stop.</li><li>For more information on prescribing oral glucocorticoids, see the CKS topic on <a class=\"topic-reference external-reference\" href=\"/topics/corticosteroids-oral/\">Corticosteroids - oral</a>.</li></ul></li><li><strong>Do not start long-term glucocorticoids before seeking specialist advice.</strong></li></ul></li><li>Consider offering a nonsteroidal anti-inflammatory drug (NSAID) at the lowest effective dose for the shortest possible<strong> </strong>time<strong> </strong>— for example, a standard NSAID such as ibuprofen, naproxen, or diclofenac, <em>or</em> a coxib (such as celecoxib or etoricoxib).<ul><li>Take account of potential gastrointestinal, liver and cardio-renal toxicity, and the person's risk factors, including age and pregnancy.</li><li>If an NSAID is prescribed, also offer a proton pump inhibitor (PPI) and review risk factors for adverse events regularly.</li><li>For more information, see the CKS topic on <a class=\"topic-reference external-reference\" href=\"/topics/nsaids-prescribing-issues/\">NSAIDs - prescribing issues</a>.</li></ul></li></ul><!-- end field ab3ef5a9-535a-4fe7-a6c6-11dde6cdaaf2 --><!-- end item e18069ee-efb8-4c92-8988-dbaa03de34e9 -->","subChapters":[{"id":"e680099d-c62c-5544-bc61-0e0231ed5305","slug":"other-causes-of-worsening-joint-symptoms","fullItemName":"Other causes of worsening joint symptoms","depth":4,"htmlHeader":"<!-- begin field 2673579c-b646-4669-afc1-f3cb269ac604 --><h4>Other causes of worsening joint symptoms</h4><!-- end field 2673579c-b646-4669-afc1-f3cb269ac604 -->","summary":null,"htmlStringContent":"<!-- begin item c6e83164-8e7b-4d1d-91cc-4903a765eb70 --><!-- begin field c5b95f21-dac6-40fa-8c86-a4d173ee1cf6 --><ul><li><strong>Avascular necrosis </strong>— sudden onset of pain in a person taking glucocorticoids, in the absence of synovitis.</li><li><strong>Cervical myelopathy or nerve root compression </strong>— sudden or insidious onset of neck pain (although pain may be absent), or weakness, unsteadiness, or paraesthesia in the presence of established rheumatoid arthritis and marked destruction of peripheral joints.</li><li><strong>Comorbid conditions </strong>such as anaemia, infection.</li><li><strong>Failure of medication to control symptoms.</strong></li><li><strong>Failure to take medication regularly.</strong></li><li><strong>Osteoporotic fracture </strong>— onset of pain and immobility, or a history of minimal trauma.</li><li><strong>Psychological and social problems.</strong></li><li><strong>Secondary osteoarthritis </strong>— prolonged symptoms with muscle wasting, instability, crepitus, reduced range of movement, minimal or no synovitis.</li></ul><!-- end field c5b95f21-dac6-40fa-8c86-a4d173ee1cf6 --><!-- end item c6e83164-8e7b-4d1d-91cc-4903a765eb70 -->","subChapters":[]},{"id":"527185c6-1de3-571c-a71c-9ca4b7086cbc","slug":"basis-for-recommendation-78f","fullItemName":"Basis for recommendation","depth":4,"htmlHeader":"<!-- begin field b2eee9be-c5d0-40c9-b988-b07facb359a7 --><h4>Basis for recommendation</h4><!-- end field b2eee9be-c5d0-40c9-b988-b07facb359a7 -->","summary":null,"htmlStringContent":"<!-- begin item 78fc2d3e-7f0b-488c-8c9b-bcedc3c53b80 --><!-- begin field 0180fe81-fcf3-41e4-86e7-1aa774d98e39 --><p>These recommendations are based on National Institute for Health and Care Excellence (NICE) guideline <em>Rheumatoid arthritis: national clinical guideline for management and treatment in adults </em>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/rheumatoid-arthritis/references/\">National Collaborating Centre for Chronic Conditions, 2018</a>], Canadian Rheumatology Association (CRA) <em>Recommendations for pharmacological management of rheumatoid arthritis with traditional and biologic disease-modifying antirheumatic drugs</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/rheumatoid-arthritis/references/\">CRA, 2012</a>], the American College of Rheumatology <em>(</em>ACR)<em> Guideline for the treatment of rheumatoid arthritis</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/rheumatoid-arthritis/references/\">ACR, 2015</a>] the Scottish Intercollegiate Guidelines Network (SIGN) guideline <em>Management of early rheumatoid arthritis </em>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/rheumatoid-arthritis/references/\">SIGN, 2011</a>], the <em>British National Formulary</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/rheumatoid-arthritis/references/\">BNF 76, 2018</a>], the manufacturers' Summaries of Product Characteristics for Depo-Medrone 40mg/ml [<a class=\"bibliography-reference internal-reference\" href=\"/topics/rheumatoid-arthritis/references/\">ABPI, 2018</a>] and Kenalog intra-articular/intramuscular injection [<a class=\"bibliography-reference internal-reference\" href=\"/topics/rheumatoid-arthritis/references/\">ABPI, 2017</a>], and what CKS considers good clinical practice.</p><h5>Assessment</h5><ul><li>The recommendation to exclude other conditions in people suspected of having a flare of rheumatoid arthritis (RA) is pragmatic, based on what CKS considers to be good clinical practice.<ul><li>Always consider possible septic arthritis in the differential diagnosis of mono-oligo flare in RA [<a class=\"bibliography-reference internal-reference\" href=\"/topics/rheumatoid-arthritis/references/\">SIGN, 2011</a>].</li></ul></li></ul><h5>Glucocorticoids </h5><ul><li>The evidence for the use of steroids in established RA is sparse and of limited quality. However, steroids (oral, intramuscular and intra-articular) are often used both in the initial presentation of disease and during flare-ups to obtain symptomatic benefit and to achieve disease control whilst waiting for the more slowly-acting DMARDS to take effect, despite the lack of evidence to support this [<a class=\"bibliography-reference internal-reference\" href=\"/topics/rheumatoid-arthritis/references/\">National Collaborating Centre for Chronic Conditions, 2018</a>]. <ul><li>NICE states that the clinical efficacy of this approach is so well established that it is doubtful that any future randomised controlled clinical trials would ever be conducted, and the guideline development group felt that there should, therefore, be a recommendation endorsing this use of steroids, both for those patients with newly diagnosed rheumatoid arthritis who are not already receiving steroids as part of DMARD combination therapy, and for the management of flare-ups in those with recent-onset or established disease.</li><li>Intra-articular injections have a limited evidence-base, but their users and receivers can testify that they are extremely useful for a flare in one or more joints.</li><li>NICE gives no preference on the type of glucocorticoid, or route of administration.</li></ul></li><li>The CRA acknowledged the anecdotal evidence regarding efficacy of glucocorticoids for managing flares (and as bridge therapy) and agreed it should be used in low doses and tapered rapidly [<a class=\"bibliography-reference internal-reference\" href=\"/topics/rheumatoid-arthritis/references/\">CRA, 2012</a>].  <ul><li>When choosing a route of administration, intramuscular or intra-articular steroids allow more control over the total cumulative dose and may be preferred in certain situations. Intra-articular steroids were agreed to be particularly useful for controlling residual synovitis if a few swollen joints remain, as they avoid systemic toxicity.</li><li>Glucocorticoids should be used at the lowest possible dose and tapered as rapidly as clinically feasible.</li></ul></li><li>The ACR also recommends that glucocorticoids should be considered for use short term (less than 3 months) for RA flares. However, it states that the recommendation is conditional because the evidence is of very low quality, and the risk/benefit ratio of glucocorticoid therapy is favourable as long as the dose is low and duration of therapy is short, but did not provide any dosage recommendations [<a class=\"bibliography-reference internal-reference\" href=\"/topics/rheumatoid-arthritis/references/\">ACR, 2015</a>]. </li><li>CKS could find no guidelines or evidence to indicate the dose of oral glucocortiocids that should be used to manage RA flare. The dose of oral glucocorticoids for a flare is based on expert opinion from reviewers of this CKS topic.</li></ul><h5>Analgesia</h5><ul><li>NICE does not make any specific recommendations on the choice of analgesia for use in flares of disease. However, it recommends that nonsteroidal anti-inflammatory drugs (NSAIDs) should be considered when control of pain or stiffness is inadequate [<a class=\"bibliography-reference internal-reference\" href=\"/topics/rheumatoid-arthritis/references/\">National Collaborating Centre for Chronic Conditions, 2018</a>]. <ul><li>The evidence for use of analgesics other than NSAIDs is highly limited.</li></ul></li><li>A Cochrane systematic review on the safety of NSAIDs in people receiving methotrexate for inflammatory arthritis concluded that 'in the management of rheumatoid arthritis, the concurrent use of NSAIDs with methotrexate appears to be safe provided appropriate monitoring is performed' [<a class=\"bibliography-reference internal-reference\" href=\"/topics/rheumatoid-arthritis/references/\">Colebatch et al, 2011</a>].</li></ul><!-- end field 0180fe81-fcf3-41e4-86e7-1aa774d98e39 --><!-- end item 78fc2d3e-7f0b-488c-8c9b-bcedc3c53b80 -->","subChapters":[]}]},{"id":"5a26acd4-c9cf-5df4-a5e4-aa3981073698","slug":"diet-complementary-therapy","fullItemName":"Diet and complementary therapy","depth":3,"htmlHeader":"<!-- begin field aee91fbc-a5d7-4ef4-b026-f22f948a12c2 --><h3>What advice should I give about diet and complementary therapy for people with rheumatoid arthritis?</h3><!-- end field aee91fbc-a5d7-4ef4-b026-f22f948a12c2 -->","summary":null,"htmlStringContent":"<!-- begin item 114b1357-f452-4cd7-b080-a0e6df0c0121 --><!-- begin field 80f6fce0-4da3-45f1-8b1d-566d6a397f5c --><ul><li>Inform adults with rheumatoid arthritis (RA) who wish to experiment with their diet that there is no strong evidence that their arthritis will benefit. However, advise them about the benefits of a Mediterranean diet (plenty of fruit, vegetables, and fish; and less meat and butter), stopping smoking, and drinking only sensible amounts of alcohol, to reduce the risk of cardiovascular disease. </li><li>Advise the person that although some complementary therapies may provide short-term symptomatic benefit, there is little or no evidence for their long-term efficacy in RA.<ul><li>If complementary therapy is being considered, explain that it should not replace prescribed medical treatment.</li></ul></li></ul><!-- end field 80f6fce0-4da3-45f1-8b1d-566d6a397f5c --><!-- end item 114b1357-f452-4cd7-b080-a0e6df0c0121 -->","subChapters":[{"id":"0d4fd217-001c-53b8-a172-94814ef44ed1","slug":"basis-for-recommendation-1b4","fullItemName":"Basis for recommendation","depth":4,"htmlHeader":"<!-- begin field d54cec49-8672-470d-92fa-b1f0a91bcab3 --><h4>Basis for recommendation</h4><!-- end field d54cec49-8672-470d-92fa-b1f0a91bcab3 -->","summary":null,"htmlStringContent":"<!-- begin item 1b406496-a36b-4940-9c70-9ecc22f61ae2 --><!-- begin field 31e4a6d0-d4bd-4e3b-89b0-4c14cdb60b89 --><p>This recommendation is based on the National Institute for Health and Care Excellence (NICE) guideline <em>Rheumatoid arthritis in adults: management </em>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/rheumatoid-arthritis/references/\">NICE, 2018a</a>]. </p><!-- end field 31e4a6d0-d4bd-4e3b-89b0-4c14cdb60b89 --><!-- end item 1b406496-a36b-4940-9c70-9ecc22f61ae2 -->","subChapters":[]}]},{"id":"f8d2960e-cb8f-55cb-9d80-d876000d66ad","slug":"referral-for-surgery","fullItemName":"Referral for surgery","depth":3,"htmlHeader":"<!-- begin field d647c6b0-bace-41a0-828d-33b37c29c484 --><h3>When is a referral to a surgeon indicated in rheumatoid arthritis?</h3><!-- end field d647c6b0-bace-41a0-828d-33b37c29c484 -->","summary":null,"htmlStringContent":"<!-- begin item f6fbad8b-4bf7-4c33-9254-f81ec7395ddc --><!-- begin field fddaf675-69a0-48a6-97ad-3f3708d5f140 --><ul><li><strong>Offer to refer people with rheumatoid arthritis (RA) for an early specialist surgical opinion if any of the following do not respond to optimal non-surgical management:</strong><ul><li>Persistent pain due to joint damage or other identifiable soft tissue cause.</li><li>Worsening joint function.</li><li>Progressive deformity.</li><li>Persistent localized synovitis.</li></ul></li><li><strong>Offer to refer people with</strong><strong> any of the following complications for a specialist surgical opinion before damage or deformity becomes irreversible: </strong><ul><li>Imminent or actual tendon rupture.</li><li>Nerve compression (for example carpal tunnel syndrome).</li><li>A stress fracture.</li></ul></li><li><strong>Offer urgent combined medical and surgical management to adults with RA who have suspected or proven septic arthritis </strong>(especially in a prosthetic joint).</li><li>For people referred for surgery, explain the benefits: <ul><li>Pain relief.</li><li>Improvement, or prevention of further deterioration, of joint function.</li><li>Prevention of deformity.</li></ul></li><li>If an adult with RA develops any symptoms or signs that suggest cervical myelopathy, request an urgent MRI scan, and refer for a specialist surgical opinion.</li><li>Do not let concerns about the long-term durability of prosthetic joints influence decisions to refer younger people with RA for joint replacements.</li></ul><!-- end field fddaf675-69a0-48a6-97ad-3f3708d5f140 --><!-- end item f6fbad8b-4bf7-4c33-9254-f81ec7395ddc -->","subChapters":[{"id":"16f90cc2-20bd-5642-a00c-4f29255b7aa4","slug":"basis-for-recommendation-97b","fullItemName":"Basis for recommendation","depth":4,"htmlHeader":"<!-- begin field 8ac8ee0b-a296-41d0-808d-852e69e167b1 --><h4>Basis for recommendation</h4><!-- end field 8ac8ee0b-a296-41d0-808d-852e69e167b1 -->","summary":null,"htmlStringContent":"<!-- begin item 97b0a770-3d19-41a7-bf71-4336b2b7e834 --><!-- begin field 05a005be-b581-4a61-a3d1-d8c07f046eb6 --><p>These recommendations are based on the National Institute for Health and Care Excellence (NICE) guideline <em>Rheumatoid arthritis: the management of rheumatoid arthritis </em>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/rheumatoid-arthritis/references/\">NICE, 2018a</a>]. </p><!-- end field 05a005be-b581-4a61-a3d1-d8c07f046eb6 --><!-- end item 97b0a770-3d19-41a7-bf71-4336b2b7e834 -->","subChapters":[]}]}]}}},"staticQueryHashes":["3666801979"]}